The TCEANC2 antibody targets the TCEANC2 protein, also known as Transcription Elongation Factor A N-Terminal and C-Terminal Domain Containing 2. a less characterized member of the transcription elongation factor family. TCEANC2 is hypothesized to regulate RNA polymerase II-mediated transcription elongation, potentially influencing gene expression by interacting with transcriptional machinery or chromatin-modifying complexes. Although its exact biological role remains unclear, studies suggest involvement in cellular processes like cell cycle regulation and DNA repair. The antibody is primarily utilized in research to detect TCEANC2 expression in various tissues and cell lines via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Emerging evidence links TCEANC2 dysregulation to diseases, including certain cancers, where altered expression may correlate with tumor progression or therapeutic resistance. Commercial availability of TCEANC2 antibodies facilitates exploration of its functional significance and interactions within transcriptional networks. However, limited literature and functional data underscore the need for further investigation to elucidate its precise mechanisms and pathophysiological relevance.